Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Inherited Erythromelalgia

Neurological & Neuromuscular

Inherited Erythromelalgia (IEM) Clinical Trials

Also called erythromelalgia, IEM, primary erythromelalgia, familial erythromelalgia, hereditary erythromelalgia

Inherited erythromelalgia is caused by gain-of-function mutations in SCN9A, the gene encoding the Nav1.7 voltage-gated sodium channel expressed primarily in pain-sensing neurons of the dorsal root ganglia.

In plain words, inherited erythromelalgia is a rare condition passed down in families that causes attacks of burning pain in the feet and hands. A gene change makes pain nerves fire too easily, so warmth or exercise can set off pain, redness and heat in the skin.

Get an email when new Inherited Erythromelalgia trials open or the FDA decides. Get alerts

Inherited Erythromelalgia

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names Inherited Erythromelalgia yet.

Inherited Erythromelalgia has no FDA-approved medicines, 0 open or active clinical trials (0 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for Inherited Erythromelalgia

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Inherited Erythromelalgia

These mutations lower the activation threshold of the channel and slow its deactivation, causing peripheral nociceptive neurons to fire excessively in response to normally tolerable warmth. The resulting neuronal hyperexcitability produces the characteristic burning pain, while sympathetic dysregulation causes localized vasodilation, redness, and warmth in the extremities.

Keep reading about Inherited Erythromelalgia

Episodes are typically triggered by increased body temperature from exercise, warm environments, or wearing closed shoes. Patients often develop elaborate cooling behaviors to manage pain, including prolonged cold water immersion, which can itself cause tissue damage. The condition is distinct from secondary erythromelalgia, which occurs as a complication of myeloproliferative disorders or other conditions.

Diagnosis is confirmed through genetic testing for SCN9A mutations. Current treatment is largely empirical, with sodium channel blockers like mexiletine showing benefit in some patients. Kv7 potassium channel openers represent a newer therapeutic approach being studied in clinical trials.

What are the symptoms of Inherited Erythromelalgia?

These are common symptoms of Inherited Erythromelalgia, and how strong they are varies from person to person.

  • Recurrent episodes of intense burning pain in the feet, hands, or both
  • Visible redness (erythema) during pain episodes
  • Warmth and swelling of affected extremities
  • Pain triggered or worsened by heat, exercise, warm environments, or standing
  • Symptom relief from cooling (cold water, ice packs, fans)
  • Episodes lasting minutes to hours, sometimes days
  • Skin damage from repeated cold immersion to relieve pain
  • Sleep disruption due to nighttime flares
  • Progressive worsening of episodes over years in some patients
  • Potential spread from feet to hands and other extremities over time

Who gets Inherited Erythromelalgia?

Inherited erythromelalgia typically begins in childhood, though people with mild symptoms may have their first pain episode later in life. The condition follows autosomal dominant inheritance, meaning an affected parent has a 50% chance of passing the mutation to each child.

Males and females are affected equally. There is significant variation in severity even within the same family carrying the same SCN9A mutation. The condition occurs across all ethnic groups with no known predilection.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Inherited Erythromelalgia

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Inherited Erythromelalgia resources

Reputable organizations and medical references for learning more about Inherited Erythromelalgia, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Inherited Erythromelalgia

This Inherited Erythromelalgia clinical trial finder lists studies as they become available, with eligibility criteria in plain English. Every trial comes from ClinicalTrials.gov.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

No active clinical trials yet

Inherited Erythromelalgia is a classified rare disease, but clinical trial activity for it is limited. That's part of why we track it. When a trial opens, Trial Friend will have it.

Get an email the moment a Inherited Erythromelalgia trial is registered on ClinicalTrials.gov.

Inherited Erythromelalgia patient communities

Facebook groups, Reddit communities and YouTube channels where Inherited Erythromelalgia patients, caregivers and advocacy groups talk.

Companies developing Inherited Erythromelalgia treatments

Drugmakers that list Inherited Erythromelalgia in their rare disease portfolio, 2 in all.

Questions people ask about Inherited Erythromelalgia